This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CAT-192
Description: CAT-192 is a human monoclonal antibody that neutralizes active TGF-beta1.
Deal Structure: In September 2000, CAT entered into a broad strategic alliance with Genzyme General to develop and commercialise human therapeutic monoclonal antibodies directed against TGF beta. Genzyme received an exclusive worldwide licence to CAT's TGF beta-specific antibodies, for all indications except ophthalmology. Research, development and commercialisation are being funded jointly and the companies will share profits. Genzyme made an equity investment in CAT. Additionally, Genzyme has received a non-exclusive worldwide licence from CAT for non-antibody antagonists of TGF beta in exchange for milestones and royalties.
In June 2006, CAT became a subsidiary of AstraZeneca.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange...See full deal structure in Biomedtracker
Additional information available to subscribers only: